Abstract
Breast cancer therapeutic intervention continues to be ambiguous owing to the lack of strategies for targeted transport and receptor-mediated uptake of drugs by cancer cells. In addition to this, sporadic tumor microenvironment, prominent restrictions with conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer cells possess a big challenge to even otherwise optimal and efficacious breast cancer treatment strategies. Surface-modified nanomedicines can expedite the cellular uptake and delivery of drug-loaded nanoparticulate constructs through binding with specific receptors overexpressed aberrantly on the tumor cell. The present review elucidates the interesting yet challenging concept of targeted delivery approaches by exploiting different types of nanoparticulate systems with multiple targeting ligands to target overexpressed receptors of breast cancer cells. The therapeutic efficacy of these novel approaches in preclinical models is also comprehensively discussed in this review. It is concluded from critical analysis of related literature that insight into the translational gap between laboratories and clinical settings would provide the possible future directions to plug the loopholes in the process of development of these receptor-targeted nanomedicines for the treatment of breast cancer.
Highlights
MRP1 is the first member of the C subfamily and act as a lipophilic anion efflux transporter with a broad substrate specificity that is expressed in a wide variety of organ and cell including breast cancer
Advancement in the therapeutic approach of breast cancer has been significantly improved by the surface-modified nanomedicine
The therapeutic effect of the human epidermal growth factor receptor 2 (HER2) decorated NPs was 12.74-fold and 13.11-fold greater than that of the untargeted NPs and higher than taxols in terms of IC50 value, respectively [74]. These studies conclude that nanotechnology-based targeting of antineoplastic agents against ErbB receptors can be further explored to enhance their therapeutic efficacy against various breast cancers
Summary
Breast cancer has an extensive history, dating back more than 3500 years to around. According to WHO, in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally [5]. Breast cancer had been diagnosed in 7.8 million women in the previous five years until the end of 2020, making it the most prevalent cancer worldwide [5]. The primary risk factor for breast cancer includes gender, genetic factor, hormonal therapy, lifestyle and dietary habits, and growing age [3,6,7]. Treatment options for breast cancer include surgery (mastectomy and lumpectomy), radiation, chemotherapy, and hormone therapy. A comprehensive account of surface-modified nanomedicines is discussed that improve the efficacy of loaded therapeutics for breast cancer treatment. The key challenges that need to be addressed to improve the utility of receptor-targeted nanomedicines in clinical settings are discussed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
